|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Pediatric Neuro-Oncology |
Baylor College of Medicine, Houston, TX 77030 [D.H.M.]; School of Medicine, State University of New York, Buffalo, NY 14222 [M.E.C., P.K.D.]; Duke University Medical Center, Durham, NC 27710 [H.S.F.]; Statistical Office, University of Florida, Gainesville, FL 32601 [J.L.K.]; St. Vincent Hospital, Green Bay, WI 54301 [L.G.]; St. Jude Children's Research Hospital, Memphis, TN 38101 [J.W.L., L.E.K.]; and Children's Hospital and Health Center, San Diego, CA 92123 [H.E.J.]
2 Address reprint requests to Pediatric Oncology Group, Operations Office, 645 N. Michigan Ave., Suite 910, Chicago, IL 60611. Address correspondence to Donald H. Mahoney, Jr., Pediatric Oncology, MC 3-3320, Baylor College of Medicine, 6621 Fannin St., Houston, TX 77030.
Abstract
The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either neuro-imaging or symptomatic evidence of progressive OPTs. Twenty-one of 50 had evidence of neurofibromatosis type I (NF-1). Therapy consisted of carboplatin 560 mg/m2 at 4-week intervals. Patients with stable disease or better after two courses were continued on therapy for 18 months or until progressive disease. Of the 50 eligible children, 39 had stable disease or better, and 34 completed the 18-month therapy. Our data are sufficient to conclude that the proportion of objective responses (complete, partial, or minor response or stable disease) exceeded 30% (P < 0.00001), and the approximate 95% confidence interval estimate of the objective response rate was 0.665 to 0.895. Twenty-one patients went off protocol because of progressive disease. Fifteen patients progressed during the 18-month therapy, and 6 patients progressed after completing therapy. Six children died with progressive disease. Major toxicities were neutropenia and thrombocytopenia, and 3 children experienced allergic reactions. Carboplatin is active and safe for the treatment of young children with progressive OPTs. The addition of other potentially active drugs may further increase the event-free survival for these children.
This article has been cited by other articles:
|
|
 |
|
  S. R. Burzynski The Present State of Antineoplaston Research (1) Integr Cancer Ther, March 1, 2004; 3(1): 47 - 58. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Quinn, D. A. Reardon, A. H. Friedman, J. N. Rich, J. H. Sampson, J. M. Provenzale, R. E. McLendon, S. Gururangan, D. D. Bigner, J. E. Herndon II, et al. Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma J. Clin. Oncol., February 15, 2003; 21(4): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Massimino, F. Spreafico, G. Cefalo, R. Riccardi, J. D. Tesoro-Tess, L. Gandola, D. Riva, A. Ruggiero, L. Valentini, E. Mazza, et al. High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma J. Clin. Oncol., October 15, 2002; 20(20): 4209 - 4216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gururangan, C. M. Cavazos, D. Ashley, J. E. Herndon II, C. S. Bruggers, A. Moghrabi, D. L. Scarcella, M. Watral, S. Tourt-Uhlig, D. Reardon, et al. Phase II Study of Carboplatin in Children With Progressive Low-Grade Gliomas J. Clin. Oncol., July 1, 2002; 20(13): 2951 - 2958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E.G. Hassall, A. E. Mitchell, and D. M. Ashley Carboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: Three case studies and a review of the literature Neuro-oncol, October 1, 2001; 3(4): 251 - 257. [PDF]
|
|
|
|
